Kinsale Capital Managent, the Dublin hedge fund manager run by the low-key, high-powered former Merrill Lynch bankers Gearoid Doyle and Seán Ó’Flannag(...)

Elan put itself up for sale in June after rejecting a number of hostile bids from private equity firm Royal Pharma. Photograph:John Cogill/Bloomberg News.

Biotech company Elan reported a $13.8 million loss in the third quarter as costs associated with the proposed takeover by pharmaceuticals firm Perr(...)

British business secretary Vince Cable said he thought it probable the exchequer would retain its 81 per cent shareholding in RBS for the majority of the next parliament. Photograph: Stefan Rousseau/PA Wire

British business minister Vince Cable has indicated that Ulster Bank parent RBS will be in public hands for another five years, according to the Sunda(...)

Elan chief executive Kelly Martin, a former  Merrill Lynch banker, took the helm in 2003, drastically paring down the company and opting to focus on the development of multiple sclerosis drug Tysabri.  Photograph: Alan Betson

The sale of Elan to Perrigo marks the end of a rollercoaster ride for the Irish drugmaker, which has fended off three takeover bids by private equity (...)

Daybreak will act as an outsourced contractor, providing IT systems and backup to Elan and other biotech firmsbinary code

Up to 50 high-end engineering jobs will be created in Dublin through a new biotech systems management company headed up by Irish expats in Silicon Val(...)

On Monday, shareholders gather in Dublin, potentially to decide the fate of the company

Shareholders at Elan have seen a lot through the years. But even they must be nonplussed by the frantic claim and counterclaim being put about by the (...)

Former Elan board member Jack Schuler has questioned the experience  of the drug company’s management. Photo: Bloomberg

Elan has dismissed criticism from a former director who questioned the ability and competence of the board to transform itself into a royalties driven(...)

The idea started when Pablo Legorreta came across an innovative scheme pioneered by Paine Webber bankers.

It may be Dublin-based, but Royalty Pharma was unknown even here until it announced its interest in acquiring Elan, Ireland’s largest indigenous pharm(...)

Elan chief executive Kelly Martin has announced deals including a $1 billion investment in Theravance Inc’s royalties.  Photograph: Alan Betson/The Irish Times

Elan Corporation’s board of directors has unanimously rejected a higher takeover offer from Royalty Pharma, an investor in royalty streams from pharma(...)

Elan chief executive Kelly Martin: “There’s always a Plan B and a C.” Photograph: Alan Betson

Irish drug-maker Elan will lay out an alternative strategy if shareholders reject a string of planned deals and thereby make a bid from a US-based inv(...)